$16M Third-Party-Funded IV Bag Plant Targets $450M Annual Revenue
CJMB sits 19% above its 52-week low of $0.383 on elevated volume (7.1× avg).
Summary
Callan JMB will break ground this month on a $16M IV bag facility at its Atlas Complex, fully funded by a non-dilutive, non-interest-bearing third-party partnership. Management projects $450M in annual revenue once operational — $300M from standard IV bags and $150M from premixed drug bags — a transformative figure against a company that just posted a 17% revenue decline and a going concern warning in its Q2 10-Q. The structure matters: no new debt and no dilution, a contrast to the $10M convertible preferred Reger Oil deal and the $75M Hexstone equity line that have weighed on the share count. Execution risk is high — this is an early-stage capacity build with no firm offtake agreements or regulatory clearances disclosed, and the October 16 8-K flagged a Nasdaq stockholders' equity deficiency. Watch for construction milestones and any signed offtake contracts before treating the $450M projection as bankable.
At the time of this announcement, CJMB was trading at $0.45 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.38 to $5.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.